Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024

6/24/24 2:59:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TERN alert in real time by email

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21 – 24, 2024 in Orlando, FL.

Get the next $TERN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TERN

Date	Price Target	Rating	Analyst
10/31/2024	$82.00	Outperform	Oppenheimer
6/22/2023	$16.00	Buy	Mizuho
6/7/2023	$18.00	Buy	Jefferies
5/31/2023	$23.00	Buy	ROTH MKM
5/8/2023	$18.00	Outperform	BMO Capital Markets
2/14/2023	$17.00	Mkt Outperform	JMP Securities
2/7/2023	$19.00	Buy	UBS
9/12/2022	$6.00	Neutral	H.C. Wainwright

More analyst ratings

$TERN
Leadership Updates

Live Leadership Updates

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
11/18/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
Top-line data from Phase 1 trial of TERN-601 (oral GLP-1) for obesity expected in September 2024 Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL) in chronic myeloid leukemia (CML) expected in December 2024 Cash, cash equivalents and marketable securities of $225 million, expected to provide runway into 2026 FOSTER CITY, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial res
8/5/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
FOSTER CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Elona Kogan, Esq., as chief legal officer, effective immediately. Ms. Kogan brings a wealth of industry experience and has successfully guided several biotechnology companies through transformational growth and transactions. "Elona's proven leadership and deep industry knowledge make her an ideal addition to the Terns team," said Amy Burroughs, chief executive officer of
7/29/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care

$TERN
Press Releases

Fastest customizable press release news feed in the world

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide
11/18/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701 (allosteric BCR-ABL tyrosine kinase inhibitor) in chronic myeloid leukemia (CML) expected in early December 2024 Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25 Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028 FOSTER CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecu
11/12/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November. UBS Global Healthcare ConferenceFormat: Fireside Chat Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PTLocation: Terranea Resort, Rancho Palos Verdes Jefferies London Healthcare Conference Format: Fireside Chat Date and Time: Tuesday, November 19, 2024 at 5
11/6/24 4:05:00 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care

$TERN
Market Insights

Live Market Insights

Kenneth Griffin Reports 5.3% Passive Stake In Terns Pharmaceuticals As Of July 10
- SEC Filing
7/22/24 4:22:11 PM ET
$TERN
Biotechnology: Pharmaceutical Preparations
Health Care
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. In the last two sessions, they have dropped by over 10%, registering the worst two-day downside since March 2020. Similarly, shares of Dutch pharmaceutical giant Novo Nordisk A/S fell 4%. Chart: Eli Lilly’s Worst Session In Over Three Years Image: Benzinga Pro Weight-Loss Market Sees New Entrants “This week is a pr
7/18/24 4:59:12 PM ET
$AMGN
$AZN
$LLY
$NVO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from Benzinga Pro. Conagra Brands shares declined 3.9% to $27.70 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Kazia Therapeutics Limited (NASDAQ:KZIA) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced result
7/11/24 2:02:49 PM ET
$AAL
$ASNS
$ASTH
$BDRX
Air Freight/Delivery Services
Consumer Discretionary
Telecommunications Equipment
Telecommunications

Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024

Chat with this insight

Recent Analyst Ratings for $TERN

$TERN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Oppenheimer initiated coverage on Terns Pharmaceuticals with a new price target

Mizuho initiated coverage on Terns Pharmaceuticals with a new price target

Jefferies initiated coverage on Terns Pharmaceuticals with a new price target

$TERN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Turner Heather D

SEC Form 3 filed by new insider Turner Heather D

Director Lu Hongbo bought $4,999,995 worth of shares (476,190 units at $10.50) (SEC Form 4)

$TERN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Lu Hongbo bought $4,999,995 worth of shares (476,190 units at $10.50) (SEC Form 4)

Yoon Seokho Bryan bought $21,272 worth of shares (4,791 units at $4.44), increasing direct ownership by 5% to 91,940 units (SEC Form 4)

Vignola Mark J. bought $21,272 worth of shares (4,791 units at $4.44), increasing direct ownership by 5% to 91,940 units (SEC Form 4)

$TERN Leadership Updates

Live Leadership Updates

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

$TERN Financials

Live finance-specific insights

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

$TERN Press Releases

Fastest customizable press release news feed in the world

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

$TERN Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

$TERN SEC Filings

Terns Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Terns Pharmaceuticals Inc.

SEC Form 10-Q filed by Terns Pharmaceuticals Inc.

$TERN Market Insights

Live Market Insights

Kenneth Griffin Reports 5.3% Passive Stake In Terns Pharmaceuticals As Of July 10

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Recent Analyst Ratings for
$TERN

$TERN
Analyst Ratings

$TERN
Insider Trading

$TERN
Insider Purchases

$TERN
Leadership Updates

$TERN
Financials

$TERN
Press Releases

$TERN
Large Ownership Changes

$TERN
SEC Filings

$TERN
Market Insights